Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Favorite
Tweet
Print
Matthew L. Sherman, MD
Deciphera Pharmaceuticals, LLC
Poster(s):
(P 358) EFFECT OF A HIGH-FAT MEAL ON THE PHARMACOKINETICS (PK) OF VIMSELTINIB, AN ORAL INHIBITOR OF THE COLONY-STIMULATING FACTOR 1 RECEPTOR (CSF1R), IN HEALTHY PARTICIPANTS
(P 376) EFFECT OF ITRACONAZOLE (ITZ) AND RABEPRAZOLE (RBP) ON THE PHARMACOKINETICS (PK) OF VIMSELTINIB, AN ORAL INHIBITOR OF THE COLONY-STIMULATING FACTOR 1 RECEPTOR, IN HEALTHY PARTICIPANTS
(P 422) EFFICACY WITH VIMSELTINIB IN PATIENTS (PTS) WITH TENOSYNOVIAL GIANT CELL TUMOR (TGCT) AND PRIOR COLONY-STIMULATING FACTOR 1 (CSF1) INHIBITOR THERAPY: A PHASE 2 CASE SERIES
(P 424) AN OPEN-LABEL PHASE 1/2 STUDY OF DCC-3009 MONOTHERAPY IN PATIENTS (PTS) WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR (GIST)
